News
Latest clinical findings based on real cases shows Aviptadil has remarkable outcomes in ARDS
A recent case-based clinical study conducted by the Medical Services of Zuventus Healthcare Limited, India has demonstrated that Aviptadil lowers the need for oxygen requirement and increases in PaO 2 :FiO 2 ratio in moderate to severe ARDS patients.
Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening lung condition where there is fluid accumulation in the alveoli, leading to reduced oxygen exchange and difficulty breathing. While the condition is well studied, there still lies a considerable mortality associated with ARDS. Aviptadil, a synthetic form of human vasoactive intestinal peptide (VIP) is approved in India ‘For the treatment of patients with severe COVID-19 with acute respiratory distress syndrome’.
In this report, a total of 5 cases with moderate to severe ARDS were treated with Aviptadil infusion for 3 consecutive days. In all these cases, there was improvement in oxygenation and reduction in the signs of respiratory distress. Three patients had maintained normal oxygen saturation on room air after 3 days of treatment. These cases highlighted the very specific role of Aviptadil in treating ARDS.
There are other cases reported from Houston Methodist Research Institute, Houston, USA, which show remarkable results in improving conditions and stabilising patients with ARDS. It can concluded that Aviptadil has the potential for saving lives in those with ARDS.
Source: Dewan B. Aviptadil in acute respiratory distress syndrome: case series. Ejpmr, 2023, 10(3), 250-253
.png)
%20(1).png)
Aviptadil has the potential to improve survival in patients with damaged pulmonary epithelium
A US Food and Drug Administration (USFDA) investigational new drug clearance analysis established that Aviptadil improves survival in patients who had acute respiratory distress syndrome (ARDS) with sepsis and were on mechanical ventilation.
The mortality associated with ARDS ranges from 35-45% and is dependent on how severe the disease is. To add to this, mechanical ventilation is the only therapy. In the setting of COVID-19, ARDS remains to be a challenging respiratory condition causing enormous levels of inflammation which can eventually lead to hypoxemia and respiratory failure.
Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) , is cleared by the US FDA as an investigational use to treat Critical COVID-19 with respiratory failure. In a study by Youssef and colleagues on 8 patients with ARDS associated with sepsis and on mechanical ventilation, Aviptadil was administered at a dosage of 60pmol/kg-100pmol/kg/ hour by intravenous infusion for 12 hours. Of the 8 patients, 7 patients weere successfully removed from mechanical ventilation and discharged from intensive care. Among the patients who were discharged, 6 patients had a successful 30-day mortality. With a promising benefit of survival in a setting where there is 50% chance of survival, Aviptadil is deemed a promising therapeutic option.
Reference: Youssef, J.G.; Said, S.; Youssef, G.; Javitt, M.J.; Javitt, J.C. Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide. Preprints.org 2020, 2020070453.